Candel Therapeutics (NASDAQ:CADL - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08, Zacks reports.
Candel Therapeutics Trading Down 5.6%
Shares of CADL stock traded down $0.36 on Thursday, hitting $6.04. The stock had a trading volume of 1,130,156 shares, compared to its average volume of 1,055,338. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.64 and a quick ratio of 4.64. The firm has a market capitalization of $302.62 million, a P/E ratio of -4.51 and a beta of -0.88. Candel Therapeutics has a 1 year low of $3.79 and a 1 year high of $14.60. The company's 50 day moving average price is $5.82 and its 200-day moving average price is $6.37.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in Candel Therapeutics by 31.5% during the 2nd quarter. Geode Capital Management LLC now owns 903,970 shares of the company's stock valued at $4,575,000 after acquiring an additional 216,509 shares during the last quarter. Rhumbline Advisers grew its holdings in Candel Therapeutics by 63.6% during the 2nd quarter. Rhumbline Advisers now owns 54,498 shares of the company's stock valued at $276,000 after buying an additional 21,196 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Candel Therapeutics by 28.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,520 shares of the company's stock valued at $109,000 after buying an additional 4,772 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Candel Therapeutics by 36.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 19,533 shares of the company's stock valued at $99,000 after buying an additional 5,270 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Candel Therapeutics during the 2nd quarter valued at $70,000. 13.93% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
CADL has been the subject of several research analyst reports. Wall Street Zen upgraded Candel Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. HC Wainwright raised Candel Therapeutics to a "buy" rating and set a $23.00 price objective on the stock in a report on Monday, June 30th. Finally, Brookline Capital Management raised Candel Therapeutics to a "strong-buy" rating in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $22.00.
View Our Latest Report on CADL
Candel Therapeutics Company Profile
(
Get Free Report)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Candel Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.
While Candel Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access